Shares of Blueprint Medicines Corp (NASDAQ:BPMC) have been assigned a consensus rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat.com reports. Two analysts have rated the stock with a sell recommendation and eight have assigned a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $98.67.

A number of research analysts have issued reports on BPMC shares. BidaskClub cut shares of Blueprint Medicines from a “hold” rating to a “sell” rating in a report on Wednesday, July 25th. Cowen reaffirmed a “buy” rating on shares of Blueprint Medicines in a report on Wednesday, August 1st. ValuEngine raised shares of Blueprint Medicines from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 2nd. Guggenheim started coverage on shares of Blueprint Medicines in a report on Tuesday, September 18th. They issued a “buy” rating and a $102.00 target price for the company. Finally, Leerink Swann started coverage on shares of Blueprint Medicines in a report on Tuesday, September 25th. They issued an “outperform” rating and a $105.00 target price for the company.

In other news, insider Marion Dorsch sold 2,300 shares of the stock in a transaction that occurred on Monday, September 17th. The shares were sold at an average price of $70.47, for a total value of $162,081.00. Following the sale, the insider now directly owns 2,300 shares in the company, valued at $162,081. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Jeffrey W. Albers sold 20,000 shares of the stock in a transaction that occurred on Monday, November 5th. The shares were sold at an average price of $63.49, for a total transaction of $1,269,800.00. Following the completion of the sale, the chief executive officer now owns 20,000 shares in the company, valued at $1,269,800. The disclosure for this sale can be found here. 3.15% of the stock is owned by corporate insiders.

Several hedge funds have recently added to or reduced their stakes in BPMC. Xact Kapitalforvaltning AB boosted its position in Blueprint Medicines by 15.0% during the second quarter. Xact Kapitalforvaltning AB now owns 6,151 shares of the biotechnology company’s stock worth $390,000 after acquiring an additional 800 shares during the last quarter. Vident Investment Advisory LLC boosted its position in Blueprint Medicines by 14.9% during the second quarter. Vident Investment Advisory LLC now owns 7,077 shares of the biotechnology company’s stock worth $449,000 after acquiring an additional 916 shares during the last quarter. Candriam Luxembourg S.C.A. boosted its position in Blueprint Medicines by 2.3% during the third quarter. Candriam Luxembourg S.C.A. now owns 45,000 shares of the biotechnology company’s stock worth $3,513,000 after acquiring an additional 1,000 shares during the last quarter. Swiss National Bank boosted its position in Blueprint Medicines by 1.9% during the second quarter. Swiss National Bank now owns 68,500 shares of the biotechnology company’s stock worth $4,348,000 after acquiring an additional 1,300 shares during the last quarter. Finally, Jennison Associates LLC boosted its position in Blueprint Medicines by 0.8% during the third quarter. Jennison Associates LLC now owns 222,540 shares of the biotechnology company’s stock worth $17,371,000 after acquiring an additional 1,658 shares during the last quarter. Institutional investors and hedge funds own 99.82% of the company’s stock.

Blueprint Medicines stock traded up $0.58 during mid-day trading on Thursday, reaching $60.36. The company had a trading volume of 346,198 shares, compared to its average volume of 426,459. Blueprint Medicines has a 1 year low of $57.31 and a 1 year high of $109.00. The company has a current ratio of 10.05, a quick ratio of 10.05 and a debt-to-equity ratio of 0.03. The stock has a market cap of $2.64 billion, a PE ratio of -15.40 and a beta of 1.46.

Blueprint Medicines (NASDAQ:BPMC) last issued its earnings results on Tuesday, October 30th. The biotechnology company reported ($1.66) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($1.57) by ($0.09). Blueprint Medicines had a negative net margin of 455.15% and a negative return on equity of 36.72%. The company had revenue of $1.10 million during the quarter, compared to analysts’ expectations of $1.87 million. During the same period last year, the business posted ($0.96) earnings per share. The company’s quarterly revenue was down 86.4% on a year-over-year basis. On average, sell-side analysts forecast that Blueprint Medicines will post -5.25 EPS for the current fiscal year.

Blueprint Medicines Company Profile

Blueprint Medicines Corporation, a biopharmaceutical company, develops drugs of small molecule kinase inhibitors that target genomic drivers in various cancers and a rare genetic disease. Its lead drug candidates include avapritinib, which is in Phase I clinical trials that targets KIT Exon 17 mutant proteins and PDGFRa D842V mutations, that are drivers of cancer and proliferative disorders, including gastrointestinal stromal tumors and systemic mastocytosis; and BLU-554, which is in Phase I clinical trials an orally available, potent, and irreversible inhibitor of the kinase FGFR4 that is activated in a defined subset of patients with hepatocellular carcinoma.

Read More: Cash Flow Analysis in Stock Selection

Analyst Recommendations for Blueprint Medicines (NASDAQ:BPMC)

Receive News & Ratings for Blueprint Medicines Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Blueprint Medicines and related companies with MarketBeat.com's FREE daily email newsletter.